Alligator Bioscience provides an update on mitazalimab
Lund, Sweden – 10 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Change in number of shares and votes in Alligator Bioscience AB
During March 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)
The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...
Alligator Bioscience publishes Annual Report for 2025
Lund, Sweden, 26 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2025, as well ...
Alligator Bioscience AB announces outcome of exercise of warrants series TO 14
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026
Lund, Sweden – 18 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience strengthens intellectual property protection for bispecific antibody platform
Lund, Sweden – 10 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...